The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process ...

Robert F. Kennedy Jr. told the Senate Finance Committee that he is not anti-vaccine during his confirmation hearing for ...

The Inflation Reduction Act of 2022 has triggered a raft of changes to Medicare Part D plans and Medicare Advantage plans that affect prescription drug coverage in 2025. Here’s what to know.

New letters urge the Centers for Medicare & Medicaid Services to expand Medicare and Medicaid to include FDA-approved ...

Donald Trump has rescinded an executive order from President Joe Biden that sought to lower the price of drugs.

During the first round of negotiations last year, prices of some of the most commonly used drugs in Medicare were slashed by approximately 40 to 80 percent, according to a statement from President ...

said in a statement. Late last year, the Centers for Medicare & Medicaid Services announced it had reached pricing deals with companies for 10 drugs in the inaugural round of negotiations.

Forward-looking Statements This news release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private ...

The Centers for Medicare and Medicaid Services (CMS ... of the statute,” a Novo Nordisk spokesperson said in a statement. “Even as our IRA lawsuit progresses, we remain committed to working ...

slashing the price of some of the most commonly used drugs in Medicare by about 40 to 80%," Biden said in a statement issued by the White House Friday. "The Inflation Reduction Act put the country ...

said in a statement. Late last year, the Centers for Medicare & Medicaid Services announced it had reached pricing deals with companies for 10 drugs in the inaugural round of negotiations.

Medicare Part D spent the least on Otezla at $995 million, with 31,000 enrollees who used that medication, according to the fact sheet. In separate statements, Bristol Myers Squibb, Teva ...